Driven By The Use of Premium-Priced Branded Agents, The HIV Drug Market Will Experience Robust Annual Growth Through 2012
The new Pharmacor report entitled HIV finds that the increasing use ofBristol-Myers Squibb/Gilead's Atripla, Gilead/Japan Tobacco's Truvada andBristol-Myers Squibb's Reyataz in early lines of therapy, coupled withcontinuing uptake of Johnson & Johnson's Prezista, Merck's Isentress andPfizer's Selzentry in highly treatment-experienced patients will fuel thenear-term growth in the HIV market. The use of Prezista and Isentress isexpected to increase once their labels expand to include treatment initiationin asymptomatic patients.
Based on the drug's efficacy and safety profile demonstrated in clinicaltrials to date, interviewed thought leaders perceive Johnson & Johnson'srilpivirine as the most promising HIV agent in late stages of development,according to the report. Additionally, new market entrants from Merck andPfizer from the integrase inhibitors and CCR5 antagonist classes,respectively, are providing highly treatment-experienced patients with greatlyneeded additional therapeutic options.
"The increasingly wider use of premium-priced marketed products such asAtripla, Truvada, and Reyataz in early lines of therapy will be the majorgrowth driver of the HIV market over the next decade," said Sylvia Eash,Ph.D., analyst at Decision Resources. "These antiretroviral agents willcontinue to be dominate players in this market with forecasted sales,combined, of more than $5 billion in 2017."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in marketresearch publications, advisory services, and consulting designed to helpclients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
SOURCE Decision Resources
You May Also Like